Reich, K. (2022) “Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial”, Dermatology Practical & Conceptual, 12(2), p. e2022104. doi:10.5826/dpc.1202a104.